In the first Phase II trial, DM-71 showed statistically significant declines in HbA1c, fructosamine and weight with an excellent safety profile in humans, the company said. This second
Lilly said that it has been co-operating with the government in its investigation since it began in 2004. As part of the resolution, Lilly has agreed to plead
Operating revenue was $3.71 billion, a 25% increase from $2.97 billion in the fourth quarter of 2007. US product sales for the fourth quarter of 2008 were $2.5
In December 2006, Halozyme entered into an agreement with Roche to apply Halozyme’s Enhanze technology to Roche’s biological therapeutic compounds. Under the terms of the agreement, Roche paid
This is the second licensing agreement between the two companies concerning Merrion’s Gipet technology – the first agreement for the development of oral insulin analogs was signed in
In his most recent endeavor, Faulkner served as president, chief executive officer (CEO) and member of the board of directors of Digene Corporation, a Nasdaq-traded company prior to
“The opportunity that lies in front of Abraxis BioScience is enormous and is a result of the validated science underlying the company’s proprietary nab(R) technology in the clinical
“bioMérieux performed well in the fourth quarter in a much more challenging economic environment,” commented chief executive officer Stéphane Bancel. “Full-year sales rose 7.5% like-for-like, meeting the targets
This new facility, Abbott’s first pharmaceutical R&D site in Southeast Asia, will conduct stability studies, including studies on active pharmaceutical ingredients and novel formulations, to support global regulatory
In this role, Mr Pred is responsible for overseeing all US manufacturing operations. Most recently, Mr Pred led all manufacturing in a multi-plant operation for vaccine production for
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.